The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.

The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.

These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.

Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.

The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Continuing education is, therefore, essential for clinicians to stay informed about the efficacy and safety data for these systemic therapy options.

Studies suggest a benefit of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk in carriers of a BRCA1/2 pathogenic/likely pathogenic (P/LP) variant, but the magnitude of the effect is not well-understood, and evidence is mixed regarding age at which RRSO should be undertaken and the specific P/LP variant (BRCA1 vs. BRCA2) carried. More data are needed regarding the efficacy of salpingectomy without oophorectomy in reducing the risk for ovarian cancer in carriers of a BRCA1/2 P/LP variant.

Multidisciplinary involvement, including nursing and palliative care specialists, is key to providing the best care possible for patients with recurrent/refractory ovarian cancer.

This activity will address the increasing use of PARP inhibitors in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.